Navigation Links
Solta Medical Reports First Quarter Results
Date:5/1/2012

contingent consideration liability

$0.08$0.00Acquisition-related expenses

$0.00$0.00Severance expenses

$0.00$0.00Stock-based compensation

$0.02$0.01Non-GAAP basic net income (loss) per share

($0.01)$0.01Non-GAAP diluted net income (loss) per share

($0.01)$0.01GAAP weighted average shares outstanding used in calculating basic net loss per share

61,352,52459,900,703GAAP weighted average shares outstanding used in calculating diluted net loss per share

61,352,52459,900,703Adjustments for dilutive potential common stock

-4,282,730Weighted average shares outstanding used in calculating non-GAAP diluted net income (loss) per share

61,352,52464,183,433 Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)March 31, December 31,20122011ASSETSCurrent assets:Cash and cash equivalents

$11,785$17,417Accounts receivable

14,29913,282Inventories

17,35416,524Prepaid expenses and other current assets

8,1378,626Total current assets

51,57555,849Property and equipment, net

6,7676,818Purchased intangible assets, net

47,61649,352Goodwill

96,62096,620Other assets

659659Total assets

$203,237$209,298LIABILITIES AND STOCKHOLDERS' EQUITYLiabilities:Accounts payable

$6,535$5,767Accrued liabilities

15,17616,126Current portion of contingent consideration liability

16,000—Current portion of deferred revenue

4,2334,521Short-term borrowings

6,1037,441Customer deposits

1,182610Total current liabilities

49,22934,465Deferred revenue, net of current portion

721824Term loan, net of current portion

15,47316,959Non-current tax liabilities

2,9862,975Contingent consideration liability

16,50027,800Other liabilities

12292Tot
'/>"/>

SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1
2. Solta Medical Provides Update on Liposonix Launch
3. Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System
4. Solta Medical Reports Second Quarter Results
5. Solta Medical Reports First Quarter Results
6. Solta Medical to Present at the JMP Securities Research Conference
7. Solta Medical Announces First Quarter 2011 Results Release and Conference Call
8. Solta Medical Reports Fourth Quarter and Full Year 2010 Results
9. Solta Medical Announces Full Year and Fourth Quarter 2010 Results Release and Conference Call
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported ... June 28, 2014.  , Revenues were $10.6 million ... million in the 2013 second quarter and up sequentially from ... the first six months of 2014 were $20.9 million, up ... last year. , Gross margin for the quarter was ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8
... on Monday, December 10, 2007, NEW HAVEN, Conn., ... today announced that preliminary data,from its pivotal Phase II ... acute myelogenous leukemia (AML) would be presented,in a poster ... in,Atlanta, Georgia on Saturday, December 8, 2007., The ...
... 5 Replidyne, Inc.,(Nasdaq: RDYN ) announced today ... participate on the New and Powerful Anti-infectives,panel at the ... take place at 11:00 am ET on Thursday, December ... City., A live audio webcast of the panel ...
Cached Medicine Technology:Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 2Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 3
(Date:8/1/2014)... iFitDress.com, one of the most famous dress suppliers in the ... dresses online. At the moment, all the brand new ... According to the company’s senior spokesman, the special offer will ... stock is limited. Those who are thinking of buying cheap ... possible. All its products are delicately made by top designers. ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Parker Waichman ... rights of victims injured by defective medical devices and ... be recalling its Ethicon surgical power morcellator devices used ... sited concerns involving the spread of cancer associated with ... dated July 31, 2014. , Johnson & Johnson ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... expanding care and care management,company, BRENTWOOD, Tenn., ... care management for the frail elderly,announced today that ... has been appointed to its board of directors., ... management company focused on,improving the quality of life ...
... The Smart Circle,International, LLC, the nation,s leader in ... Health Associates, Inc.,has put together the first-ever National ... and wellness-based physicians that,see preventative and maintenance care ... States., Thomas Edison once stated, "The doctor ...
... Available in Time for Spring Allergy ... ... Zagat Survey(R) guide, launched today, offers people with,seasonal and year-round allergies an ... and tips on how to manage their,allergy symptoms so they can enjoy ...
... Latest SmartSlide ... ... Board: WGBS), a leading developer of,state-of-the-art gene expression, genotyping, cell biology ... SmartSlide 200,Micro-Incubation System, the latest offering in its SmartSlide product,line. The ...
... Physicians and,Nurses Against Tobacco, Inc., (PANAT) an ... petitioning Pope Benedict,XVI to condemn the production, distribution, ... of State, to declare the Vatican the first ... political, spiritual, and moral leader,to set an example ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... and informatics products, announced that,Mexico,s Instituto de ... Estado (ISSSTE) ordered 282 electrocardiograph systems (ECGs) ... Science history. Instrumentation,Technologies de Mexico, Cardiac Science,s ...
Cached Medicine News:Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 2Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 3Health News:Smart Circle International, LLC Launches Its National Health and Wellness Network Complimentary 1/2-Hour Massage for Everyone 2Health News:20-City Zagat Survey(R) Guide Spotlights Outdoor Destinations and Offers Allergy Management Tips 2Health News:20-City Zagat Survey(R) Guide Spotlights Outdoor Destinations and Offers Allergy Management Tips 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 2Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 4Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 5Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 6Health News:Physicians and Nurses Against Tobacco (PANAT) Petition Pope Benedict XVI to Condemn Tobacco Industry, and Tobacco Use, and Declare Vatican First Tobacco- Free Country 2Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 2Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 3Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 4
... ready-to-use solutions ideal for a wide range ... prepared with 18 megOhm water, filtered using ... sterile bottles., Reliable - Manufactured according ... lot-to-lot consistency. , High Quality - ...
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
Medicine Products: